1. Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives 
Andrzej Jakubowiak 
Seminars in Hematology 
Volume 49, Pages S16-S32 (July 2012)
DOI: /j.seminhematol
Copyright © 2012 Elsevier Inc. Terms and Conditions

2. Figure 1
Treatment of relapsed/refractory multiple myeloma. Abbreviations: allo-SCT, allogeneic stem cell transplantation; auto-SCT, autologous stem cell transplantation; CRD, cyclophosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, cyclophosphamide, bortezomib, and dexamethasone; Cy, cyclophosphamide; Dex, dexamethasone; Len, lenalidomide; MPT, melphalan, prednisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PegLD, pegylated liposomal doxorubicin; PN, peripheral neuropathy; Thal, thalidomide; VMP, bortezomib, melphalan, and prednisone; VTD, bortezomib, thalidomide, and dexamethasone. *Indicates that data are available from a phase 3 randomized trial. †Only if PN has recovered and there is no other therapeutic alternative.
From Ludwig H, et al. Oncologist 2010;15: Copyright 2010 by Alphamed Press. Reproduced with permission of Alphamed Press. Permission conveyed through Copyright Clearance Center, Inc.
Seminars in Hematology  , S16-S32DOI: ( /j.seminhematol )
Copyright © 2012 Elsevier Inc. Terms and Conditions